Signal from the longevity frontier
Short, sourced takes on the breakthroughs that matter — what happened, why it matters, and where the field goes next. Educational commentary, not medical advice.
A review of a 2026 Nature Aging study from Barabási’s lab that maps aging’s hallmarks across the human protein network and flags already-approved drugs worth repurposing — validated against mouse and human trial data.
Read →Enzymes that clear molecular damage plus partial epigenetic reprogramming that resets the aging clock — how they combine, and a grounded look at how, by whom, and where they may first be delivered.
Read →A 2026 Nature Communications study reports an engineered enzyme that strips a major advanced glycation end-product out of aged human tissue — pushing 75-year-old aorta and skin back toward 30-year-old levels.
Read →